FEATURED COMPANIES
- Amgen
- Intas Pharmaceuticals
- Novartis
- Partner Therapeutics
- MORE
1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
About Chemotherapy-induced Neutropenia Therapeutics
Neutrophils are immunity-inducing white blood cells. Reduction in its number causes neutropenia. Chemotherapy-induced neutropenia occurring during treatment increases patient’s risk of infection and disrupts cancer treatment.
The analysts forecast the Global Chemotherapy-Induced Neutropenia Therapeutics Market to grow at a CAGR of 5.52% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the global chemotherapy-induced neutropenia therapeutics market. To calculate the market size, the report considers the revenue generated from the adoption of CIN treatment.
The market is divided into the following segments based on geography:
Key vendors
Neutrophils are immunity-inducing white blood cells. Reduction in its number causes neutropenia. Chemotherapy-induced neutropenia occurring during treatment increases patient’s risk of infection and disrupts cancer treatment.
The analysts forecast the Global Chemotherapy-Induced Neutropenia Therapeutics Market to grow at a CAGR of 5.52% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the global chemotherapy-induced neutropenia therapeutics market. To calculate the market size, the report considers the revenue generated from the adoption of CIN treatment.
The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA
Key vendors
- Amgen
- Intas Pharmaceuticals
- Novartis
- Partner Therapeutics
- Teva Pharmaceuticals Industries
- Rapid development in molecular oncology
- For a full, detailed list, view the full report
- Lack of accessibility and affordability of cancer therapy in developing countries
- For a full, detailed list, view the full report
- Technological advancements
- For a full, detailed list, view the full report
- What will the market size be in 2022 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Amgen
- Intas Pharmaceuticals
- Novartis
- Partner Therapeutics
- MORE
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
PART 09: REGIONAL LANDSCAPE
PART 11: DRIVERS AND CHALLENGES
Exhibit 01: Related market
Exhibit 02: Market characteristics
Exhibit 03: Market segments
Exhibit 04: Market definition - Inclusions and exclusions checklist
Exhibit 05: Market size 2017
Exhibit 06: Validation techniques employed for market sizing 2017
Exhibit 07: Global - Market size and forecast 2017-2022 ($ mn)
Exhibit 08: Global - Year-over-year growth 2018-2022 (%)
Exhibit 09: Five forces analysis 2017
Exhibit 10: Five forces analysis 2022
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2017
Exhibit 17: Procedure - Market share 2017-2022 (%)
Exhibit 18: Comparison by procedure
Exhibit 19: G-CSF therapy - Market size and forecast 2017-2022 ($ mn)
Exhibit 20: G-CSF therapy - Year-over-year growth 2018-2022 (%)
Exhibit 21: Granulocyte transfusion - Market size and forecast 2017-2022 ($ mn)
Exhibit 22: Granulocyte transfusion - Year-over-year growth 2018-2022 (%)
Exhibit 23: Antibiotic therapy - Market size and forecast 2017-2022 ($ mn)
Exhibit 24: Antibiotic therapy - Year-over-year growth 2018-2022 (%)
Exhibit 25: Splenectomy - Market size and forecast 2017-2022 ($ mn)
Exhibit 26: Splenectomy - Year-over-year growth 2018-2022 (%)
Exhibit 27: Market opportunity by procedure
Exhibit 28: Customer landscape
Exhibit 29: Global - Market share by geography 2017-2022 (%)
Exhibit 30: Regional comparison
Exhibit 31: Americas - Market size and forecast 2017-2022 ($ mn)
Exhibit 32: Americas - Year-over-year growth 2018-2022 (%)
Exhibit 33: EMEA - Market size and forecast 2017-2022 ($ mn)
Exhibit 34: EMEA - Year-over-year growth 2018-2022 (%)
Exhibit 35: APAC - Market size and forecast 2017-2022 ($ mn)
Exhibit 36: APAC - Year-over-year growth 2018-2022 (%)
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: R&D funding for cancer for FY2013 to FY2016 ($ millions)
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendor classification
Exhibit 43: Market positioning of vendors
Exhibit 44: Amgen overview
Exhibit 45: Amgen - Business segments
Exhibit 46: Amgen - Organizational developments
Exhibit 47: Amgen - Geographic focus
Exhibit 48: Amgen - Key offerings
Exhibit 49: Intas Pharmaceuticals overview
Exhibit 50: Intas Pharmaceuticals - Business segments
Exhibit 51: Intas Pharmaceuticals - Organizational developments
Exhibit 52: Intas Pharmaceuticals - Geographic focus
Exhibit 53: Intas Pharmaceuticals - Segment focus
Exhibit 54: Intas Pharmaceuticals - Key offerings
Exhibit 55: Novartis overview
Exhibit 56: Novartis - Business segments
Exhibit 57: Novartis - Organizational developments
Exhibit 58: Novartis - Geographic focus
Exhibit 59: Novartis - Segment focus
Exhibit 60: Novartis - Key offerings
Exhibit 61: Partner Therapeutics overview
Exhibit 62: Partner Therapeutics - Business segments
Exhibit 63: Partner Therapeutics - Organizational developments
Exhibit 64: Partner Therapeutics - Geographic focus
Exhibit 65: Partner Therapeutics - Key offerings
Exhibit 66: Teva Pharmaceuticals Industries overview
Exhibit 67: Teva Pharmaceuticals Industries - Business segments
Exhibit 68: Teva Pharmaceuticals Industries - Organizational developments
Exhibit 69: Teva Pharmaceuticals Industries - Geographic focus
Exhibit 70: Teva Pharmaceuticals Industries - Segment focus
Exhibit 71: Teva Pharmaceuticals Industries - Key offerings
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market sizing 2017
- Market size and forecast 2017-2022
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
- Segmentation by procedure
- Comparison by procedure
- G-CSF therapy - Market size and forecast 2017-2022
- Granulocyte transfusion - Market size and forecast 2017-2022
- Antibiotic therapy - Market size and forecast 2017-2022
- Splenectomy - Market size and forecast 2017-2022
- Market opportunity by procedure
PART 09: REGIONAL LANDSCAPE
- Geographical segmentation
- Regional comparison
- Americas - Market size and forecast 2017-2022
- EMEA - Market size and forecast 2017-2022
- APAC - Market size and forecast 2017-2022
- Key leading countries
- Market opportunity
PART 11: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
- Increase in global awareness about cancer treatments
- Technological advancements
- Strategic alliances
- Overview
- Landscape disruption
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Amgen
- Intas Pharmaceuticals
- Novartis
- Partner Therapeutics
- Teva Pharmaceuticals Industries
- List of abbreviations
Exhibit 01: Related market
Exhibit 02: Market characteristics
Exhibit 03: Market segments
Exhibit 04: Market definition - Inclusions and exclusions checklist
Exhibit 05: Market size 2017
Exhibit 06: Validation techniques employed for market sizing 2017
Exhibit 07: Global - Market size and forecast 2017-2022 ($ mn)
Exhibit 08: Global - Year-over-year growth 2018-2022 (%)
Exhibit 09: Five forces analysis 2017
Exhibit 10: Five forces analysis 2022
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2017
Exhibit 17: Procedure - Market share 2017-2022 (%)
Exhibit 18: Comparison by procedure
Exhibit 19: G-CSF therapy - Market size and forecast 2017-2022 ($ mn)
Exhibit 20: G-CSF therapy - Year-over-year growth 2018-2022 (%)
Exhibit 21: Granulocyte transfusion - Market size and forecast 2017-2022 ($ mn)
Exhibit 22: Granulocyte transfusion - Year-over-year growth 2018-2022 (%)
Exhibit 23: Antibiotic therapy - Market size and forecast 2017-2022 ($ mn)
Exhibit 24: Antibiotic therapy - Year-over-year growth 2018-2022 (%)
Exhibit 25: Splenectomy - Market size and forecast 2017-2022 ($ mn)
Exhibit 26: Splenectomy - Year-over-year growth 2018-2022 (%)
Exhibit 27: Market opportunity by procedure
Exhibit 28: Customer landscape
Exhibit 29: Global - Market share by geography 2017-2022 (%)
Exhibit 30: Regional comparison
Exhibit 31: Americas - Market size and forecast 2017-2022 ($ mn)
Exhibit 32: Americas - Year-over-year growth 2018-2022 (%)
Exhibit 33: EMEA - Market size and forecast 2017-2022 ($ mn)
Exhibit 34: EMEA - Year-over-year growth 2018-2022 (%)
Exhibit 35: APAC - Market size and forecast 2017-2022 ($ mn)
Exhibit 36: APAC - Year-over-year growth 2018-2022 (%)
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: R&D funding for cancer for FY2013 to FY2016 ($ millions)
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendor classification
Exhibit 43: Market positioning of vendors
Exhibit 44: Amgen overview
Exhibit 45: Amgen - Business segments
Exhibit 46: Amgen - Organizational developments
Exhibit 47: Amgen - Geographic focus
Exhibit 48: Amgen - Key offerings
Exhibit 49: Intas Pharmaceuticals overview
Exhibit 50: Intas Pharmaceuticals - Business segments
Exhibit 51: Intas Pharmaceuticals - Organizational developments
Exhibit 52: Intas Pharmaceuticals - Geographic focus
Exhibit 53: Intas Pharmaceuticals - Segment focus
Exhibit 54: Intas Pharmaceuticals - Key offerings
Exhibit 55: Novartis overview
Exhibit 56: Novartis - Business segments
Exhibit 57: Novartis - Organizational developments
Exhibit 58: Novartis - Geographic focus
Exhibit 59: Novartis - Segment focus
Exhibit 60: Novartis - Key offerings
Exhibit 61: Partner Therapeutics overview
Exhibit 62: Partner Therapeutics - Business segments
Exhibit 63: Partner Therapeutics - Organizational developments
Exhibit 64: Partner Therapeutics - Geographic focus
Exhibit 65: Partner Therapeutics - Key offerings
Exhibit 66: Teva Pharmaceuticals Industries overview
Exhibit 67: Teva Pharmaceuticals Industries - Business segments
Exhibit 68: Teva Pharmaceuticals Industries - Organizational developments
Exhibit 69: Teva Pharmaceuticals Industries - Geographic focus
Exhibit 70: Teva Pharmaceuticals Industries - Segment focus
Exhibit 71: Teva Pharmaceuticals Industries - Key offerings
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Amgen
- Intas Pharmaceuticals
- Novartis
- Partner Therapeutics
- MORE
New Report Released: - Global Chemotherapy-induced Neutropenia Therapeutics Market 2018-2022.
The author of the report recognizes the following companies as the key players in the global chemotherapy-induced neutropenia therapeutics market: Amgen, Intas Pharmaceuticals, Novartis, Partner Therapeutics, and Teva Pharmaceuticals Industries.
Commenting on the report, an analyst from the research team said: “One trend affecting this market is increase in global awareness about cancer treatments.” Awareness about cancer treatments and cancer related issues across the US has increased primarily because of the continuing efforts of different organizations.
According to the report, one driver influencing this market is the rising number of patients opting for chemotherapy. The increasing use of chemotherapy and its associated risks in affecting immunity due to neutropenia, coupled with growing patient population, generate the demand for CIN therapeutics.
Further, the report states that one challenge affecting this market is the high cost of treatment. Through chemotherapy is an effective treatment for cancer, the risks associated with it, such as CIN, can lead to increase in hospital visits and longer hospital stays.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
The author of the report recognizes the following companies as the key players in the global chemotherapy-induced neutropenia therapeutics market: Amgen, Intas Pharmaceuticals, Novartis, Partner Therapeutics, and Teva Pharmaceuticals Industries.
Commenting on the report, an analyst from the research team said: “One trend affecting this market is increase in global awareness about cancer treatments.” Awareness about cancer treatments and cancer related issues across the US has increased primarily because of the continuing efforts of different organizations.
According to the report, one driver influencing this market is the rising number of patients opting for chemotherapy. The increasing use of chemotherapy and its associated risks in affecting immunity due to neutropenia, coupled with growing patient population, generate the demand for CIN therapeutics.
Further, the report states that one challenge affecting this market is the high cost of treatment. Through chemotherapy is an effective treatment for cancer, the risks associated with it, such as CIN, can lead to increase in hospital visits and longer hospital stays.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
- Amgen
- Intas Pharmaceuticals
- Novartis
- Partner Therapeutics
- Teva Pharmaceuticals Industries
Note: Product cover images may vary from those shown
LOADING...
